New test may expand olaparib benefits to more ovarian cancer patients
Knowledge-focused
Terminated
This study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC